Skip to main content
Hauptrubriken
Zeitschriften Fortbildung Hebammen Bücher Kongresse & Live-Webinare
Social Media - Folgen Sie uns!
Instagram Facebook LinkedIn Instagram Hebammen
Service
Jobbörse Kundenservice Info & Hilfe
Fokus-Themen
Chronisch-entzündliche Darmerkrankung COVID-19-Update Diabetes Hautpflege Klima & Gesundheit Hygiene Intensivpflege Kardiologische Pflege Mobilisation Nachhaltigkeit Nierenerkrankungen Obstipation Onkologische Pflege Palliativpflege Schmerz Sucht in der Pflege Vielfalt, Gleichberechtigung und Inklusion Wundversorgung
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Gerontologie und Geriatrie
Erschienen in:

01.02.2014 | Beiträge zum Themenschwerpunkt

Algorithm for anticoagulation management in geriatric hip fracture patients—Surgeons save Blood

verfasst von: M.A. Wendl-Soeldner, C.W.I. Moll, C. Kammerlander, M. Gosch, T. Roth, MD

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

During the past decades, the number of hip fractures has been increasing steadily. Perioperative thromboprophylaxis has become a routine aspect in the care of geriatric hip fracture patients. In addition, a large proportion of these patients are already anticoagulated because of internistic comorbidities before they sustained the hip fracture. Although the management of preexisting anticoagulation in both orthopedic elective and emergency procedures is well reported, proximal femoral fractures are classified as “acute” and therefore represent neither of these two categories. In this study, we review the different options of handling preexisting anticoagulation and antiaggregation as well as perioperative thromboprophylaxis. The Innsbruck Algorithm for the management of anticoagulation in geriatric hip fracture patients suggests how perioperative bleeding risk can be minimized, while still addressing the underlying disease.
Vorheriger Artikel Perioperative Risikostratifizierung geriatrischer Patienten bei nichtkardialen Eingriffen
Nächster Artikel Pharmacologic prevention of postoperative delirium
Literatur
1.
Hopkins RB et al (2012) Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 23:921–927PubMedCrossRef
2.
Nguyen ND, Ahlborg HG, Center JR et al (2007) Residual lifetime risk of fractures in women and men. J Bone Miner Res 22:781–788PubMedCrossRef
3.
Falck-Ytter Y et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 141:e278S–e325SPubMedCentralPubMedCrossRef
4.
Bucking B, Bliemel C, Waschnick L et al (2013) Anticoagulation medication for proximal femoral fractures: prospective validation study of new institutional guidelines. Unfallchirurg116:909–915
5.
Liem IS, Kammerlander C, Suhm N et al (2013) Identifying a standard set of outcome parameters for the evaluation of orthogeriatric co-management for hip fractures. Injury 44:1403–1412PubMedCrossRef
6.
Leung F, Lau TW, Kwan K et al (2010) Does timing of surgery matter in fragility hip fractures? Osteoporos Int 21:S529–S534PubMedCrossRef
7.
Khan SK, Kalra S, Khanna A et al (2009) Timing of surgery for hip fractures: a systematic review of 52 published studies involving 291,413 patients. Injury 40:692–697PubMedCrossRef
8.
9.
Luger TJ et al (2010) Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter? Osteoporos Int 21:555–572CrossRef
10.
Ashouri F, Al-Jundi W, Patel A, Mangwani J (2011) Management of warfarin anticoagulation in patients with fractured neck of femur. ISRN Hematol 2011:294628PubMedCentralPubMed
11.
Kammerlander C et al (2011) The Tyrolean Geriatric Fracture Center: an orthogeriatric co-management model. Z Gerontol Geriatr 44:363–367PubMedCrossRef
12.
Cushman M, Lim MW, Zakai FNA (2011) Clinical practice guide on anticoagulant dosing and management of anticoagulant- associated bleeding complications in adults. American College of Chest Physicians Evidence- Based Clinical Practice Guideline on Antithrombotic and Thrombolytic Therapy (8th Edition). 1–8
13.
Luxembourg B, Krause M, Lindhoff-Last E (2007) Basiswissen Gerinnungslabor. Dtsch Ärztebl 21:1489–1498
14.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed
15.
Jackson CMC, Esnouf MPM, Lindahl TLT (2002) A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 33:43–51CrossRef
16.
17.
Dager WE, Gosselin RC, Kitchen S, Dwyre D (2012) Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 46:1627–1636PubMedCrossRef
18.
Eerenberg ES et al (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579PubMedCrossRef
19.
Janssen Pharmaceuticals, Inc. XARELTO® [package insert]. janssenmedicalinformation.com at (http://​www.​janssenmedicalin​formation.​com/​assets/​pdf/​products/​files/​Xarelto/​pi/​ENC-010330-11.​pdf)
20.
Funk DMA (2012) Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012:460–465PubMed
21.
Eikelboom JWJ, Quinlan DJD, Douketis JDJ (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:7–7CrossRef
22.
Chassot PG, Delabays A, Spahn DR (2007) Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99:316–328PubMedCrossRef
23.
Thaler HW et al (2013) Stressulkusprophylaxe, Thromboseprophylaxe und Gerinnungsmanagement bei Patienten mit Hüftfrakturen. Wien Med Wochenschr. doi:10.1007/s10354-013-0234-0
24.
ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Regionalanästhesie unter gerinnungshemmender Medikation. oegari.at (2013). http://​www.​oegari.​at/​web_​files/​dateiarchiv/​116/​Regionalan%C3%A4sthesie%20und%20Gerinnungshemmer%202013.pdf. Accessed 23 Jan 2014
25.
Friedman PAP, Rosenberg RDR, Hauschka PVP, Fitz-James AA (1977) A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta 494:271–276PubMedCrossRef
26.
Douketis JD et al (212) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 141:e326S–e350S
27.
Quinlan DJ, Eikelboom JW, Weitz JI (2013) Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation 128:1179–1181PubMed
28.
Department of Surgical Education, Orlando Regional Medical Center (2012) Warfarin Reversal Guideline. 1–8
29.
Ansell J et al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:160S–198SPubMedCrossRef
30.
Bonow RO et al (2008) focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 52:e1–e142PubMedCrossRef
31.
Smith EB, Parvizi J, Purtill JJ (2011) Delayed surgery for patients with femur and hip fractures—risk of deep venous thrombosis. J Trauma 70:E113–E116PubMedCrossRef
32.
Gage BF et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef
33.
Gage BF et al (2004) Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 110:2287–2292PubMedCrossRef
34.
Keeling D et al (2011) Guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 154:311–324PubMedCrossRef
35.
Jaffer AK, Brotman DJ, Chukwumerije N (2003) When patients on warfarin need surgery. Cleve Clin J Med 70:973–984PubMedCrossRef
36.
Bhatia M, Talawadekar G, Parihar S, Smith A (2010) An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture. Ann R Coll Surg Engl 92:473–476PubMedCentralPubMedCrossRef
37.
38.
Rucci P, Claviés M-C, Donat F, Necciari J (2002) Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 41(Suppl 2):11–18CrossRef
39.
Glaxo Group Ltd. Arixtra® Product Information. ema.europa.eu. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​000403/​WC500027746.​pdf.​ Accessed 23 Jan 2014
40.
Boneu B et al (1995) Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost 74:1468–1473PubMed
41.
Donat F et al (2002) The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 41(Suppl 2):1–9PubMedCrossRef
42.
EMA European Medicines Agency. EPAR summary for the public: Arixtra® fondaparinux sodium. ema.europa.eu (2010) http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Summary_​for_​the_​public/​human/​000403/​WC500027736.​pdf.​ Accessed 23 Jan 2014
43.
ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Perioperatives ‘Bridging’ der neuen oralen Antikoagulationen. oegari.at (2012) http://​www.​oegari.​at/​web_​files/​dateiarchiv/​116/​Perioperatives%20Bridging%20der%20Neuen%20Oralen%20Antikoagulantien%202012.pdf.
44.
EMA European Medicines Agency. EPAR summary for the public: Xarelto® rivaroxaban. ema.europa.eu (2013) http://​www.​ema.​europa.​eu/​ema/​index.​jsp?​curl=​pages/​medicines/​human/​medicines/​000944/​human_​med_​001155.​jsp&​mid=​WC0b01ac058001d1​24.​ Accessed 23 Jan 2014
45.
Kubitza D, Becka M, Wensing G et al (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880PubMedCrossRef
46.
Bayer Health Care Manufacturing Srl. Xarelto® EPAR Product information. ema.europa.eu. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​000944/​WC500057108.​pdf.​ Accessed 23 Jan 2014
47.
ÖGARI—Österreichische Gesellschaft für Anästhesiologie und Intensivmedizin. Gerinnungsmanagement bei traumatisch bedingter Massivblutung. oegari.at (2013) http://​www.​oegari.​at/​web_​files/​dateiarchiv/​116/​Gerinnungsmanage​ment%20bei%20traumatisch%20bedingter%20Massivblutung2013.pdf
48.
EMA European Medicines Agency. Pradaxa® EPAR summary for the public. ema.europa.eu (2012) (http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Summary_​for_​the_​public/​human/​000829/​WC500041060.​pdf.​ Accessed 23 Jan 2014
49.
Ridgefield, C.T. Boehringer Ingelheim Pharma GmbH & Co. KG. Dabigatran etexilate (Pradaxa®) for the treatment of atrial fibrillation. package insert
50.
Blech S, Ebner T, Ludwig-Schwellinger E et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36:386–399PubMedCrossRef
51.
Lehr T et al (2012) Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 52:1373–1378PubMedCrossRef
52.
Boehringer Ingelheim Pharma GmbH & Co. KG. Pradaxa® EPAR Product Information. ema.europa.eu. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​000829/​WC500041059.​pdf- Accessed 23 Jan 2014
53.
Tohgi H, Konno S, Tamura K et al (1992) Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 23:1400–1403PubMedCrossRef
54.
Raithel M et al (2005) Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol 56(Suppl 5):89–102PubMed
55.
Hawkey CJ, Langman MJS (2003) Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52:600–608PubMedCentralPubMedCrossRef
56.
Beckerath von NN et al (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112:2946–2950
57.
Eikelboom JWJ, Hirsh JJ, Spencer FAF et al (2012) Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e89S–e119SPubMedCentralPubMedCrossRef
58.
Li CC, Hirsh JJ, Xie CC et al (2012) Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 10:521–528PubMedCrossRef
59.
Gerstein NS, Schulman PM, Gerstein WH et al (2012) Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg 255:811–819PubMedCrossRef
60.
Collet JP et al (2004) Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110:2361–2367PubMedCrossRef
61.
Iakovou I et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef
62.
Sharma AK et al (2004) Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 63:141–145PubMedCrossRef
63.
National Institute For Health And Clinical Excellence (2011) The management of hip fracture in adults. 124 (nice.org.uk)
64.
Leonidou A, Rallan R, Cox N et al (2013) Comparison of different warfarin reversal protocols on surgical delay and complication rate in hip fracture patients. J Orthop Surg (Hong Kong) 21:142–145
Metadaten
Titel
Algorithm for anticoagulation management in geriatric hip fracture patients—Surgeons save Blood
verfasst von
M.A. Wendl-Soeldner
C.W.I. Moll
C. Kammerlander
M. Gosch
T. Roth, MD
Publikationsdatum
01.02.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 2/2014
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-013-0595-4

Weitere Artikel der Ausgabe 2/2014

Performance-Oriented Mobility Assessment und Berg Balance Scale im Vergleich

  • Übersichten

The prevalence of falls in adults aged 40 years or older in an urban, German population

  • Originalien

Pharmacologic prevention of postoperative delirium

  • Beiträge zum Themenschwerpunkt

Therapeutische Beziehung und Gesprächsführung

  • CME Zertifizierte Fortbildung

Mittteilungen der ÖGGG

  • Mitteilungen der ÖGGG

Mobile geriatrische Rehabilitation bei funktionell schwer beeinträchtigten Patienten

  • Originalien